Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MBBS, MSc, MD, Jeffrey I. Weitz, MD, Walter Ageno, Yoriko De Sanctis, MS, Wentao Lu, PhD, Jianfeng Xu, PhD, John Albanese, BS, MBA, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 163.

https://doi.org/10.1182/blood-2019-122934

Published: 2019

Journal Articles

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Shveta Gupta, MBBS, Ayesha Zia, MD, Ravindra Sarode, MD

Blood (2019) 134 (Supplement_1): 4976.

https://doi.org/10.1182/blood-2019-129118

Published: 2019

Journal Articles

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Haoxu Ouyang, MD PhD, Ratesh Khillan, Nyein Htway Yu, MBBS, MD, Mohan Preet, MD

Blood (2019) 134 (Supplement_1): 4927.

https://doi.org/10.1182/blood-2019-132283

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery

Margarita Kushnir, MD, Radhika Gali, MD, Mariam Alexander, MD, Henny Heisler H. Billett, MD

Blood (2019) 134 (Supplement_1): 2439.

https://doi.org/10.1182/blood-2019-127645

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Alex C. Spyropoulos, MD, Gary E. Raskob, PhD, Alexander T Cohen, MBBS, MSc, MD, Walter Ageno, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Concetta Lipardi, MD PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 2441.

https://doi.org/10.1182/blood-2019-122930

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Alex C. Spyropoulos, MD, Walter Ageno, Gregory W. Albers, MD, C. Gregory Elliott, MD, Jonathan L. Halperin, MD, William R. Hiatt, Gregory Maynard, MD, P. Gabriel Steg, MD, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Gary E. Raskob, PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 3669.

https://doi.org/10.1182/blood-2019-122621

Published: 2019

Journal Articles

Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

Yimin Pearl Wang, BSc, Rohan Kehar, MDMSc,FRCPC, Alla Iansavitchene, BSc, Alejandro Lazo-Langner, MD MSc

Blood (2019) 134 (Supplement_1): 3672.

https://doi.org/10.1182/blood-2019-123870

Published: 2019

Journal Articles

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Christine G. Kohn, PharmD, Gary H. Lyman, MD MPH, Nicole M. Kuderer, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2019) 134 (Supplement_1): 3673.

https://doi.org/10.1182/blood-2019-128581

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Renata Almeida Sa, MSc, BSc, Fatimah Al-Ani, MD MRCP, Alejandro Lazo-Langner, MD MSc, Martha L Louzada, MDMSc

Blood (2019) 134 (Supplement_1): 3675.

https://doi.org/10.1182/blood-2019-121765

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Alex C. Spyropoulos, MD, Concetta Lipardi, MD PhD, Alexander T Cohen, MBBS, MSc, MD, Biljana Vučković, MD PhD, Jianfeng Xu, PhD, Wentao Lu, PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3671.

https://doi.org/10.1182/blood-2019-122945

Published: 2019

Journal Articles

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Alfonso J Tafur, MD MS, Na Li, PhD, Nathan Clark, PharmD, Sam Schulman, MD PhD FRCPC, Alex Spyropoulos, MD, Joseph A Caprini, MD MS, FACS, RVT, James Douketis, MD

Blood (2019) 134 (Supplement_1): 710.

https://doi.org/10.1182/blood-2019-125292

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Beverley J. Hunt, Matthew D. Neal, Jakob Stensballe

Blood (2018) 132 (23): 2441–2445.

https://doi.org/10.1182/blood-2018-06-850396

Published: 2018

Journal Articles

Efficacy and Safety of Direct Oral Factor Xa Inhibitors in 795 Morbidly Obese Patients

Margarita Kushnir, MD, Yun Choi, MD, Ruth Eisenberg, MS, Devika Rao, MD, Seda Tolu, MD, Jackson Gao, MD, Wenzhu Mowrey, PhD, Henny Heisler Billett, MD

Blood (2018) 132 (Supplement 1): 423.

https://doi.org/10.1182/blood-2018-99-116396

Published: 2018

Journal Articles

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Yoshiyuki Morishima, PhD, Yuko Honda, Taketoshi Furugohri, PhD

Blood (2018) 132 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2018-99-109724

Published: 2018

Journal Articles

Clinical, Laboratory, and Genetic Risk Factors for Thrombosis in Sickle Cell Disease

Andrew Srisuwananukorn, MD, Rasha Raslan, MD, Xu Zhang, PhD, Binal N. Shah, PhD, Jin Han, PharmD, PhD, Michel Gowhari, DO, Shivi Jain, MD, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Santosh L. Saraf, MD

Blood (2018) 132 (Supplement 1): 9.

https://doi.org/10.1182/blood-2018-99-115128

Published: 2018

Journal Articles

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Fakiha Siddiqui, Siddharth Mehrotra, Vishnu Venkitasubramony, Rithik Raina, Lorenzo Storino Ramacciotti, Jack Bontekoe, BS, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Jawed Fareed, PhD

Blood (2018) 132 (Supplement 1): 2520.

https://doi.org/10.1182/blood-2018-99-116993

Published: 2018

NARROW

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Efficacy and Safety of Direct Oral Factor Xa Inhibitors in Patients after Bariatric Surgery

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Efficacy and Safety of Direct Oral Factor Xa Inhibitors in 795 Morbidly Obese Patients

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Clinical, Laboratory, and Genetic Risk Factors for Thrombosis in Sickle Cell Disease

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only